Unichem Lab gains after USFDA OKs Roha plant

Unichem Laboratories rose 2.91% to Rs 184 after the company said that US drug regulator's inspection at Roha concluded successfully without any FDA form 483.

The United States Food and Drug Administration (USFDA) conducted inspection at the company's active pharmaceutical ingredients (APIs) facility at Roha from 9 to 12 September 2019. The inspection was a post approval inspection and successfully concluded without any FDA form 483 issued.

Meanwhile, the S&P BSE Sensex was down 41 points or 0.11% to 37,063.11.

On the BSE, 6083 shares were traded in the counter so far compared with average daily volumes of 6359 shares in the past one quarter. The stock hit a high of Rs 187 and a low of Rs 182.2 so far during the day.

The stock hit a 52-week high of Rs 227 on 30 Oct 2018. The stock hit a 52-week low of Rs 158.35 on 31 Jul 2019.

On a consolidated basis, Unichem Lab reported a net loss of Rs 6.19 crore in Q1 June 2019 over a net loss of Rs 20.46 crore in Q1 June 2019 over Q1 June 2018.

Unichem Laboratories is a pharmaceutical company addressing the needs of relevant and growing therapeutic areas like gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterials, anti-infectives and pain management.

Powered by Capital Market - Live News


(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel